Deontics to support US ambition for high-value care at HIMSS 2015

April 7, 2015

Clinically-led healthcare artificial intelligence provider Deontics is looking to build on its US activity by attending HIMSS 2015, the world’s health technology conference being held in Chicago in 12-16 April 2015.The firm provides physicians with a state-of-the-art clinical ‘sat nav’ for personalized care, and will seek to build on its relationships with US and UK clinical providers, electronic records companies and clinical guideline writing organizations to show how it can put actionable intelligence directly into clinical workflow.

Deontics’ products support all the key principles of the Office of the National Coordinator for Health Information Technology’s Federal Health IT Strategic Plan 2015- 2020 which aims to deliver high-value health care through, in part, the creation of evidence-based tools.

Dr Guy Wood-Gush, CEO of Deontics said: “Having already worked with organizations such as a top five US pharmaceutical company, the American Association of Consultant Endocrinologists (AACE), and a top five US hospital group, we’re keen to discuss the benefits of personalized care and our experience in this field, at HIMSS 2015.

“Our technology links scientific research and evidence into everyday clinical practice, helping providers to continuously learn, improve performance and deliver more effective and efficient patient care.”

Deontics provides robust, transparent and auditable clinical performance and resource data that can support clinical performance measurement, research, medical legal investigations and pre-authorization of treatment at an individual and population level.

Its advanced clinical pathways and decision support functionality is helping to improve patient outcomes in the US and UK. Its interoperable architecture means it can help electronic health record providers realize the potential of clinical decision support quickly and effectively.

Healthcare variation and negligence claims can be minimized through relevant use of personalized, clinical guidelines and protocols. The technology is being used to tackle major health challenges such as cancer and diabetes across the globe, and has the potential to transform clinical practice.

Deontics’ technologies are the results of long-term academic research in medical artificial intelligence originating at Carnegie Mellon University, and subsequently developed at the Medical Research Council, University of Oxford, University College London and Cancer Research UK.

Also available at the event, will be Deontics’ chief technology officer Dr Ioannis Chronakis (; +44 7813 131443), and chief medical officer Mr Vivek Patkar (; +44 7947329072).